UMIN-CTR Clinical Trial

Unique ID issued by UMIN C000000006
Receipt number R000000009
Scientific Title Lisinopril only and a combination of lisinopril and losartan for IgA nephropathy with focal mesangial proliferation in children: A randomized controlled trial of efficacy and safety
Date of disclosure of the study information 2005/08/01
Last modified on 2013/12/25 10:02:18

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Lisinopril only and a combination of lisinopril and losartan for IgA nephropathy with focal mesangial proliferation in children: A randomized controlled trial of efficacy and safety

Acronym

Lisinopril only and a combination of lisinopril and losartan: A randomized controlled trial(JSKDC01)

Scientific Title

Lisinopril only and a combination of lisinopril and losartan for IgA nephropathy with focal mesangial proliferation in children: A randomized controlled trial of efficacy and safety

Scientific Title:Acronym

Lisinopril only and a combination of lisinopril and losartan: A randomized controlled trial(JSKDC01)

Region

Japan


Condition

Condition

IgA nephropathy in children

Classification by specialty

Nephrology Pediatrics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

By comparing lisinopril only and a combination of lisinopril and losartan, the better is selected as a standard treatment for IgA nephropathy in children in our group.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Disappearance rate of proteinuria

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit


Blinding

Open -but assessor(s) are blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Lisinopril for 2 years

Interventions/Control_2

Lisinopril+losartan for 2 years

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

2 years-old <=

Age-upper limit

18 years-old >=

Gender

Male and Female

Key inclusion criteria

1.Biopsy diagnoses of IgA nephropathy with focal mesangial proliferation, where a renal biopsy has been performed within 4 months before eligibility.
2.Proteinuria with a urinary protein-creatinine ratio >0.2.
4.Aged 2 to 18 years.
5.Written informed consent from the patients' parents or legal guardians.

Key exclusion criteria

1.Other renal or systemic forms of nephrotic syndrome defined on renal biopsy, clinical features or serology (Henoch-Schönlein nephritis, systemic lupus erythematosus).
2.Medical history of allergy or hypersensitivity reactions to lisinopuril and losartan.
3.Chronic renal dysfunction.
4.Active infectious disease.
5.Severe liver disfunction.
6.History of steroid, immunosupression, ACEI and ARB administration.
7.History of Saireito or dipilidamol administration.
8.Pregnancy.
9.Judged inappropriate for this study by the physicians.

Target sample size

110


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Norishige Yoshikawa

Organization

Wakayama Medical University

Division name

Department of Pediatrics

Zip code


Address

811-1 Kimiidera Wakayama City Wakayama

TEL

073-441-0633

Email

nori@wakayama-med.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Nakanishi

Organization

Japanese Study Group of Kidney Disease in Children

Division name

Department of Pediatrics, Wakayama Medical University

Zip code


Address

811-1 KImiidera Wakayama City

TEL

073-441-0633

Homepage URL


Email

jskdc@wakayama-med.ac.jp


Sponsor or person

Institute

Japanese Study group of Kidney Disease in Children

Institute

Department

Personal name



Funding Source

Organization

The Ministry of Health,Labour and Welfare

Organization

Division

Category of Funding Organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2005 Year 08 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2004 Year 11 Month 30 Day

Date of IRB


Anticipated trial start date

2005 Year 01 Month 01 Day

Last follow-up date

2013 Year 12 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2005 Year 06 Month 14 Day

Last modified on

2013 Year 12 Month 25 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000009


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name